Artificial Intelligence (AI) continues to change at warp speed, creating a “pull” versus “push” customer engagement model where a growing percentage of people ‘pull’ the information they want today from platforms like ChatGPT or Claude, making…
Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI…
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…
EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and…
The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger? Spend more than a few minutes of…
Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by Joey Pecoraro and Christopher Nüesch from EVERSANA MANAGEMENT CONSULTING,…
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying…
Are you a pharmaceutical manufacturer looking to navigate the complex world of Integrated Delivery Networks (IDNs)? These powerful entities, which manage multiple healthcare facilities, are key players in delivering high-quality, cost-effective, and patient-centered care. But how…
Innovation is of no worth if it doesn’t provide better outcomes for patients. Indeed, such advancements should hold as centre the amelioration of the overall patient experience. And that’s where digital developments and a Direct-To-Patient (DTP)…